Spruce Biosciences, Inc. stock is up 110.32% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 February’s closed higher than January.
Spruce Biosciences, Inc. focuses on developing and commercializing novel therapies for rare endocrine disorders. The company is developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!